Carisma Therapeutics, Inc. (CARM)

Market Cap	8.02M
Revenue (ttm)	19.63M
Net Income (ttm)	-60.48M
Shares Out	41.79M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,192
Open	0.1910
Previous Close	0.2009
Day's Range	0.1860 - 0.2043
52-Week Range	0.1600 - 1.9100
Beta	2.79
Analysts	Hold
Price Target	0.90 (+350.0%)
Earnings Date	May 8, 2025

About CARM

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company’s ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: CARM
• Website: https://www.carismatx.com

Financial Performance

In 2024, Carisma Therapeutics's revenue was $19.63 million, an increase of 31.59% compared to the previous year's $14.92 million. Losses were -$60.48 million, -30.39% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for CARM stock is "Hold." The 12-month stock price forecast is $0.9, which is an increase of 350.00% from the latest price.

Price Target

$0.9

(350.00% upside)

Analyst Consensus: Hold